CN115210265A - 蛋白酶加工的分子 - Google Patents

蛋白酶加工的分子 Download PDF

Info

Publication number
CN115210265A
CN115210265A CN202180018397.5A CN202180018397A CN115210265A CN 115210265 A CN115210265 A CN 115210265A CN 202180018397 A CN202180018397 A CN 202180018397A CN 115210265 A CN115210265 A CN 115210265A
Authority
CN
China
Prior art keywords
ser
thr
gly
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180018397.5A
Other languages
English (en)
Chinese (zh)
Inventor
T·兰格
E·雷奥
S·韦尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN115210265A publication Critical patent/CN115210265A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180018397.5A 2020-03-05 2021-03-05 蛋白酶加工的分子 Pending CN115210265A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20305233.7 2020-03-05
EP20305233 2020-03-05
PCT/EP2021/055673 WO2021176090A1 (en) 2020-03-05 2021-03-05 Protease-processed molecules

Publications (1)

Publication Number Publication Date
CN115210265A true CN115210265A (zh) 2022-10-18

Family

ID=71096648

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180018397.5A Pending CN115210265A (zh) 2020-03-05 2021-03-05 蛋白酶加工的分子

Country Status (15)

Country Link
US (1) US20230279151A1 (enExample)
EP (1) EP4114865B1 (enExample)
JP (1) JP7766608B2 (enExample)
KR (1) KR20220150345A (enExample)
CN (1) CN115210265A (enExample)
AU (1) AU2021231327A1 (enExample)
BR (1) BR112022017542A2 (enExample)
CA (1) CA3170452A1 (enExample)
DK (1) DK4114865T3 (enExample)
ES (1) ES3068539T3 (enExample)
IL (1) IL295958A (enExample)
MX (1) MX2022010958A (enExample)
PL (1) PL4114865T3 (enExample)
TW (1) TW202146463A (enExample)
WO (1) WO2021176090A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025199278A2 (en) * 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Masked multispecific antigen-binding molecules with cleavable linkers

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166755A (zh) * 2005-04-26 2008-04-23 格利科菲公司 具有可切割连接物的单链抗体
WO2012025530A1 (en) * 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
WO2013006544A1 (en) * 2011-07-06 2013-01-10 Medimmune, Llc Methods for making multimeric polypeptides
WO2016046778A2 (en) * 2014-09-25 2016-03-31 Amgen Inc Protease-activatable bispecific proteins
CN106432484A (zh) * 2011-05-17 2017-02-22 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
KR101963230B1 (ko) * 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166755A (zh) * 2005-04-26 2008-04-23 格利科菲公司 具有可切割连接物的单链抗体
WO2012025530A1 (en) * 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CN106432484A (zh) * 2011-05-17 2017-02-22 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
WO2013006544A1 (en) * 2011-07-06 2013-01-10 Medimmune, Llc Methods for making multimeric polypeptides
WO2016046778A2 (en) * 2014-09-25 2016-03-31 Amgen Inc Protease-activatable bispecific proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARIO A IZIDORO ET AL.: "A study of human furin specificity using synthetic peptides derived from natural substrates, and effects of potassium ions", 《ARCH BIOCHEM BIOPHYS》, vol. 487, no. 2, 27 May 2009 (2009-05-27), pages 105 - 114 *

Also Published As

Publication number Publication date
KR20220150345A (ko) 2022-11-10
ES3068539T3 (en) 2026-06-01
JP2023516380A (ja) 2023-04-19
US20230279151A1 (en) 2023-09-07
PL4114865T3 (pl) 2026-05-25
CA3170452A1 (en) 2021-09-10
BR112022017542A2 (pt) 2022-10-18
DK4114865T3 (da) 2026-04-27
JP7766608B2 (ja) 2025-11-10
IL295958A (en) 2022-10-01
MX2022010958A (es) 2022-10-07
TW202146463A (zh) 2021-12-16
EP4114865B1 (en) 2026-01-28
AU2021231327A1 (en) 2022-10-27
WO2021176090A1 (en) 2021-09-10
EP4114865A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
ES2935274T3 (es) Anticuerpo con intercambio de dominios
JP2025023052A (ja) 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
KR102247704B1 (ko) 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
CN110520445B (zh) 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备
TW202104257A (zh) 具有突變型Ｆａｂ結構域的多特異性結合蛋白
JP7543134B2 (ja) システイン操作された抗原結合分子
JP7359784B2 (ja) 抗ｐｄ－１／抗ｈｅｒ２天然抗体構造ヘテロダイマー系の二重特異性抗体及びその製造方法
TW200932269A (en) Bivalent, bispecific antibodies
CN113056486B (zh) 改善的抗flt3抗原结合蛋白
JP2022546002A (ja) ４価の対称型二重特異性抗体
AU2026201242A1 (en) Bispecific antibodies with cleavable C-terminal charge-paired tags
CN119698294A (zh) 结合γ-δT细胞受体的变体抗体
JP7766608B2 (ja) プロテアーゼプロセシングした分子
RU2846294C1 (ru) Молекулы, получаемые посредством процессинга протеазами
CN120917053A (zh) 三特异性工程化抗体
HK40087043B (en) Protease-processed molecules
HK40087043A (en) Protease-processed molecules
KR20160103767A (ko) 신규 항-tfpi 항체 및 이를 포함하는 조성물
HK40125045A (zh) 承载有效载荷的多特异性抗体
JP2026509081A (ja) ペイロード担持多重特異性抗体
WO2025150556A1 (ja) 環境応答性ペプチドを利用したタンパク質の製造方法
KR20250169614A (ko) 최적화된 cd3 항원 결합 도메인
EA043006B1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination